218 related articles for article (PubMed ID: 23041229)
21. Enhancement of esculetin on arsenic trioxide-provoked apoptosis in human leukemia U937 cells.
Lin TH; Lu FJ; Yin YF; Tseng TH
Chem Biol Interact; 2009 Jun; 180(1):61-8. PubMed ID: 19428345
[TBL] [Abstract][Full Text] [Related]
22. Characterization of arsenic trioxide resistant clones derived from Jurkat leukemia T cell line: focus on PI3K/Akt signaling pathway.
Roszak J; Smok-Pieniążek A; Nocuń M; Stępnik M
Chem Biol Interact; 2013 Oct; 205(3):198-211. PubMed ID: 23911876
[TBL] [Abstract][Full Text] [Related]
23. Protein kinase C is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in human bladder cancer cells.
Wang Y; An R; Dong X; Pan S; Duan G; Sun X
Urol Int; 2009; 82(2):214-21. PubMed ID: 19322013
[TBL] [Abstract][Full Text] [Related]
24. Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells.
Chiu HW; Tseng YC; Hsu YH; Lin YF; Foo NP; Guo HR; Wang YJ
Cancer Lett; 2015 Jan; 356(2 Pt B):762-72. PubMed ID: 25449439
[TBL] [Abstract][Full Text] [Related]
25. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
26. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Liu ZM; Tseng JT; Hong DY; Huang HS
Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with 5-amino-4-imidazolecarboxamide riboside and arsenic trioxide in acute myeloid leukemia cells involving AMPK/TSC2/mTOR pathway.
Chen L; Han F; Qu H; Yan H; Ren L; Yang S
Pharmazie; 2013 Feb; 68(2):117-23. PubMed ID: 23469683
[TBL] [Abstract][Full Text] [Related]
29. Antitumor effects of arsenic trioxide in transformed human thyroid cells.
Fröhlich E; Czarnocka B; Brossart P; Wahl R
Thyroid; 2008 Nov; 18(11):1183-93. PubMed ID: 19014326
[TBL] [Abstract][Full Text] [Related]
30. TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
Liu ZM; Tseng HY; Cheng YL; Yeh BW; Wu WJ; Huang HS
Toxicol Appl Pharmacol; 2015 May; 285(1):41-50. PubMed ID: 25791921
[TBL] [Abstract][Full Text] [Related]
31. Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process.
Yu C; Rahmani M; Almenara J; Sausville EA; Dent P; Grant S
Oncogene; 2004 Feb; 23(7):1364-76. PubMed ID: 14647418
[TBL] [Abstract][Full Text] [Related]
32. The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation.
Dembitz V; Lalic H; Ostojic A; Vrhovac R; Banfic H; Visnjic D
Int J Hematol; 2015 Jul; 102(1):12-24. PubMed ID: 25758096
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells.
Ramos AM; Fernández C; Amrán D; Sancho P; de Blas E; Aller P
Blood; 2005 May; 105(10):4013-20. PubMed ID: 15665116
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Akt potentiates 2-DG-induced apoptosis via downregulation of UPR in acute lymphoblastic leukemia.
DeSalvo J; Kuznetsov JN; Du J; Leclerc GM; Leclerc GJ; Lampidis TJ; Barredo JC
Mol Cancer Res; 2012 Jul; 10(7):969-78. PubMed ID: 22692960
[TBL] [Abstract][Full Text] [Related]
35. Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias.
Tabellini G; Tazzari PL; Bortul R; Evangelisti C; Billi AM; Grafone T; Martinelli G; Baccarani M; Martelli AM
Br J Haematol; 2005 Sep; 130(5):716-25. PubMed ID: 16115127
[TBL] [Abstract][Full Text] [Related]
36. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
[TBL] [Abstract][Full Text] [Related]
37. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration.
Kim JH; Kim JH; Yu YS; Kim DH; Kim CJ; Kim KW
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1819-23. PubMed ID: 19060284
[TBL] [Abstract][Full Text] [Related]
39. Sustained Akt/PKB activation and transient attenuation of c-jun N-terminal kinase in the inhibition of apoptosis by IGF-1 in vascular smooth muscle cells.
Allen RT; Krueger KD; Dhume A; Agrawal DK
Apoptosis; 2005 May; 10(3):525-35. PubMed ID: 15909115
[TBL] [Abstract][Full Text] [Related]
40. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
Canestraro M; Galimberti S; Savli H; Palumbo GA; Tibullo D; Nagy B; Guerrini F; Piaggi S; Cine N; Metelli MR; Petrini M
Cancer Genet Cytogenet; 2010 Jun; 199(2):110-20. PubMed ID: 20471514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
